F. Hoffmann-La Roche AG


About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche retains sole responsibility for content © 2018 F. Hoffmann-La Roche AG. All trademarks used or mentioned in this release are protected by law.

1 October 2018 - 30 September 2019

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 October 2018 - 30 September 2019 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

Count Share
142 50.37

Outputs by subject (Share)

Subject Count Share
Life Sciences 125 41.89
Chemistry 19 8.49
Physical Sciences 5 0.93

Highlight of the month

Protein structure aids in anti-cancer drug discovery

© Monty Rakusen/Getty

© Monty Rakusen/Getty

The detailed structure of a protein implicated in cancer metastasis has revealed several promising new therapeutic leads.

Cancer cells can spread through the body via the lymphatic system and establish secondary tumours, which are responsible for about 90% of cancer deaths.

Now, a team co-led by Roche scientists has used X-ray crystallography to elucidate the structure of CC chemokine receptor 7 (CCR7) — a protein involved in helping cancer cells spread to the lymph nodes.

They also mapped the structure of CCR7 bound to an antagonist molecule and then searched computationally for drugs with similar three-dimensional shapes and other design features. One of the top matches was navarixin, a multi-target inhibitor with demonstrated anti-metastatic activity in clinical trials of patients with aggressive colon tumours. Navarixin is known to block other receptors, but CCR7 antagonism could explain part of its mechanism as well.

The findings provide a platform for further investigations of possible CCR7 inhibitors.

Supported content

  1. Cell 178, 1222–1230 (2019). doi: 10.1016/j.cell.2019.07.028

View the article on the Nature Index

See more research highlights from F. Hoffmann-La Roche AG

More research highlights from F. Hoffmann-La Roche AG

1 October 2018 - 30 September 2019

International vs. domestic collaboration by Share

  • 7.05% Domestic
  • 92.95% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the fractional count (Share), which is listed in parentheses.

Affiliated joint institutions and consortia

Return to institution outputs